Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

29 Oct 2020

Abstract excerpt

Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion. It has led to a breakthrough in the treatment of hematologic malignancies in recent years. However, unfortunately, resistance to venetoclax is inevitable. Multiple studies confirmed that the upregulation of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33292251
DOI: 10.1186/s12935-020-01614-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesPMID 33292251Read ↗

Mechanisms of venetoclax resistance and solutionsSemantic proximity Read ↗

Therapeutics targeting Bcl-2 in hematological malignanciesSemantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

Targeting Bcl-2 Proteins in Acute Myeloid LeukemiaSemantic proximity Read ↗

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity Read ↗

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical developmentSemantic proximity Read ↗

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?Semantic proximity Read ↗

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Progress in understanding the mechanisms of resistance to BCL-2 inhibitorsSemantic proximity Read ↗

The rise of apoptosis: targeting apoptosis in hematologic malignanciesSemantic proximity Read ↗

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.Semantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.